GlobeNewswire: Auris Medical AG Contains the last 10 of 191 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T10:53:19ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/07/16/2264315/0/en/Auris-Medical-Announces-Launch-of-New-Corporate-Website.html?f=22&fvtc=4&fvtv=30147Auris Medical Announces Launch of New Corporate Website2021-07-16T13:00:00Z<![CDATA[Hamilton, Bermuda, July 15, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the launch of its newly-designed corporate website www.aurismedical.com. The new website features a streamlined and modern design and also reflects the Company’s recently announced strategic repositioning.]]>https://www.globenewswire.com/news-release/2021/07/14/2262869/0/en/Auris-Medical-Announces-Publication-of-Data-from-Preclinical-Studies-with-Bentrio-Nasal-Spray-in-Prevention-and-Mitigation-of-SARS-CoV-2.html?f=22&fvtc=4&fvtv=30147Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-22021-07-14T13:00:00Z<![CDATA[Hamilton, Bermuda, July 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced additional preclinical data in a model of primary human nasal airway epithelium from its Bentrio™ (AM-301) nasal spray development program in SARS-CoV-2. AM-301 was found to be safe in vitro, and it significantly decelerated viral titer growth in experimental models of prophylaxis and mitigation. The manuscript describing these preclinical data is available on a preprint server at https://www.biorxiv.org/content/10.1101/2021.07.12.452021v1 and will undergo scientific peer-review for potential publication.]]>https://www.globenewswire.com/news-release/2021/07/06/2258288/0/en/Auris-Medical-to-Develop-KRAS-Targeting-RNA-Treatment-for-Colorectal-Cancer-as-First-Therapeutic-Indication-for-OligoPhore-Technology.html?f=22&fvtc=4&fvtv=30147Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology2021-07-06T13:00:00Z<![CDATA[Hamilton, Bermuda, July 6, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the selection of mutant KRAS-driven colorectal cancer as the first therapeutic indication for its OligoPhore™ oligonucleotide delivery platform. The Company intends to develop the treatment under project code AM-401 with submission of an IND targeted for the end of 2022.]]>https://www.globenewswire.com/news-release/2021/06/28/2253879/0/en/Auris-Medical-to-Initiate-Market-Launch-of-Bentrio-Nasal-Spray-in-Germany.html?f=22&fvtc=4&fvtv=30147Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany2021-06-28T12:30:00Z<![CDATA[Hamilton, Bermuda, June 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that its affiliate Altamira Medica Ltd. will start the market roll-out of Bentrio™, its nasal spray for protection against airborne viruses and allergens, by launching it in Germany. Bentrio™ will shortly become available through selected online pharmacies; over the coming months, market coverage will be expanded progressively through additional distribution channels and in further countries.]]>https://www.globenewswire.com/news-release/2021/06/21/2250255/0/en/Auris-Medical-Announces-Significant-Inhibition-of-Tumor-Growth-with-OligoPhore-siRNA-Targeting-NF-%CE%BAB-in-Murine-Model-of-Adult-T-Cell-Leukemia-Lymphoma.html?f=22&fvtc=4&fvtv=30147Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model of Adult T-Cell Leukemia / Lymphoma2021-06-21T12:30:00Z<![CDATA[Hamilton, Bermuda, June 21, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the publication of positive results from an in vivo study demonstrating significant inhibition of tumor growth by siRNA knock-down of NF-κB employing its OligoPhoreTM technology in Adult T-cell Leukemia Lymphoma (ATLL). The article titled "Targeting NF-κB with nanotherapy in a mouse model of adult T-cell leukemia / lymphoma” was published in Nanomaterials, an international peer-reviewed open-access journal.1]]>https://www.globenewswire.com/news-release/2021/06/03/2241209/0/en/Auris-Medical-Announces-Acquisition-of-RNA-Therapeutics-Company-and-Plans-for-Strategic-Repositioning.html?f=22&fvtc=4&fvtv=30147Auris Medical Announces Acquisition of RNA Therapeutics Company and Plans for Strategic Repositioning 2021-06-03T11:30:00Z<![CDATA[Hamilton, Bermuda, June 3, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced the acquisition of privately held Trasir Therapeutics, Inc. (“Trasir”), based in Tampa, FL, a pioneer in extrahepatic oligonucleotide delivery. The purchase price comprises 0.77 million common shares of the acquiring Company, the assumption of certain selling shareholders’ cash outlays as well as a future share-based payment contingent on reaching a specific development milestone. The transaction, which closed on June 1, 2021, is the starting point for a strategic repositioning under which the Company intends to focus on the development of RNA therapeutics while in the medium term aiming to spin off or divest its existing assets in neurotology, rhinology and allergology. Dr. Samuel Wickline, Trasir’s founder and Professor of Medicine, has been appointed Chief Scientific Officer and joined the Company’s leadership team.]]>https://www.globenewswire.com/news-release/2021/06/01/2239515/0/en/Auris-Medical-Starts-Preparations-for-Covid-19-Trial-with-Bentrio-in-India.html?f=22&fvtc=4&fvtv=30147Auris Medical Starts Preparations for Covid-19 Trial with Bentrio in India 2021-06-01T12:30:00Z<![CDATA[Hamilton, Bermuda, June 1, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergology, today announced that its affiliate Altamira Medica Ltd. has started preparations for the conduct of a study with its BentrioTM nasal spray for protection against airborne viruses and allergens in India. The study will seek to evaluate the efficacy of BentrioTM in the prevention and treatment of acute Covid-19 and shall start recruitment in the third quarter 2021 subject to regulatory and ethics committee approval.]]>https://www.globenewswire.com/news-release/2021/05/28/2238251/0/en/Auris-Medical-Holding-to-Present-at-LD-Micro-Invitational-XI-Conference.html?f=22&fvtc=4&fvtv=30147Auris Medical Holding to Present at LD Micro Invitational XI Conference 2021-05-28T12:30:00Z<![CDATA[Hamilton, Bermuda, May 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the LD Micro Invitational XI investor conference on Wednesday June 9, 2021, at 11:00 a.m. EST (Track 2). The event will be webcast live and available via the event homepage https://ldmicrojune2021.mysequire.com.]]>https://www.globenewswire.com/news-release/2021/05/25/2235582/0/en/Auris-Medical-Announces-Completion-of-Bentrio-Conformity-Assessment-Procedure-for-Marketing-in-EU.html?f=22&fvtc=4&fvtv=30147Auris Medical Announces Completion of Bentrio Conformity Assessment Procedure for Marketing in EU 2021-05-25T13:00:00Z<![CDATA[Hamilton, Bermuda, May 25, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, and its affiliate Altamira Medica Ltd. today announced that it has successfully completed the conformity assessment procedure for marketing the BentrioTM nasal spray in the member states of the European Union (EU). The product, which is intended to help protect against airborne allergens and viruses, is considered a Class I medical device under the Medical Devices Directive (MDD). BentrioTM therefore meets all essential requirements for marketing BentrioTM across Europe under the so-called CE mark.]]>https://www.globenewswire.com/news-release/2021/05/14/2229934/0/en/Auris-Medical-Reaches-Midpoint-for-Enrollment-in-Part-B-of-AM-125-Phase-2-TRAVERS-Trial-in-Acute-Peripheral-Vertigo.html?f=22&fvtc=4&fvtv=30147Auris Medical Reaches Midpoint for Enrollment in Part B of AM-125 Phase 2 TRAVERS Trial in Acute Peripheral Vertigo 2021-05-14T12:30:00Z<![CDATA[Hamilton, Bermuda, May 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that it has reached the midpoint for enrollment in Part B of its Phase 2 proof-of-concept trial of AM-125 (intranasal betahistine) in the treatment of acute peripheral vertigo.]]>